This story originally ran on Feb. 3.
Biomarker firm NextGen Sciences this week announced it has entered into an agreement with Takeda Pharmaceutical to develop validated protein biomarker assays.
Terms of the agreement were not disclosed.
The assays will be used by Takeda in preclinical and clinical studies "to support their drive toward personalized medicine," NextGen said in a statement. The company added that the assays will be designed to target specific protein isoforms found in liver and muscle in multiple species. NextGen's multiple-reaction monitoring platform will be used.